Related Experiment Video
Updated: Oct 4, 2025

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells
Published on: June 2, 2022
Nav1.5-E3 antibody inhibits cancer progression
Rui Gao1, Ting Cao1, Hui Chen1
1Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Nav1.5, a sodium channel overexpressed in cancer, was targeted by E3Ab. This antibody inhibited cancer cell migration, invasion, and tumor growth in vivo, suggesting E3Ab as a potential cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Voltage-gated sodium channel Nav1.5 is overexpressed in cancer cells, correlating with disease progression.
- Nav1.5-third extracellular region antibody (E3Ab) specifically targets Nav1.5, inhibiting its function.
- The therapeutic potential of E3Ab in cancer treatment warrants investigation.
Purpose of the Study:
- To evaluate the therapeutic potential of E3Ab in preclinical cancer models.
- To assess the effect of E3Ab on cancer cell behavior and tumor growth.
Main Methods:
- Nav1.5 expression was confirmed in Caov-3 cells via immunocytochemistry.
- In vivo tumor growth was assessed using a Caov-3 xenograft nude mouse model.
- In vitro assays evaluated the impact of E3Ab on cancer cell migration, invasion, and proliferation, with MMP-9 expression analyzed by Western blot.
Main Results:
- Caov-3 cells exhibited high Nav1.5 expression, with confirmed binding by E3Ab.
- E3Ab and lidocaine significantly inhibited Caov-3 xenograft tumor growth and reduced mitotic activity in vivo.
- In vitro, E3Ab and lidocaine suppressed cancer cell migration and invasion.
Conclusions:
- E3Ab demonstrates significant anti-cancer effects by inhibiting tumor growth, migration, and invasion.
- These findings highlight E3Ab as a promising therapeutic antibody for cancers expressing Nav1.5.
Related Concept Videos
Mitogens and the Cell Cycle
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

